|
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases
Sep 3, 2008
|
13.3 KB
|
| |
NEW YORK & SAN FRANCISCO, Sep 03, 2008 (BUSINESS WIRE) -- Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an...
|
|
|
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Sep 2, 2008
|
7.9 KB
|
| |
SAN FRANCISCO, Sept 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Wednesday, September 3, to discuss partnering plans for Dimebon.
Teleconference/Webcast Details
To participate in the live call on Wednesday, Se...
|
|
|
Medivation Announces Participation in Upcoming Conferences
Aug 28, 2008
|
8.0 KB
|
| |
SAN FRANCISCO, Aug 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
-- BioCentury's NewsMakers in the Biotech Industry on Thursday, September 4, at 9:00 a.m. Eastern Time at the Mille...
|
|
|
Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Aug 11, 2008
|
18.0 KB
|
| |
SAN FRANCISCO, Aug 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended June 30, 2008.
"Based on the significant findings of the Dimebon 12-month pivotal trial in Alzheimer's disease recently published in The Lancet, as wel...
|
|
|
Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Aug 4, 2008
|
8.0 KB
|
| |
SAN FRANCISCO, Aug 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2008 progress and provide a general business update on Monday, August 11, 2008, at 4:30 p.m. Eastern time. A financial results press re...
|
|
|
Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Aug 1, 2008
|
7.9 KB
|
| |
SAN FRANCISCO, Aug 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, at 11:15 a.m. Eastern Time at the Millennium Broadway Hotel in N...
|
|
|
MEDIVATION PRESENTS POSITIVE NEW DATA ON DIMEBON'S LONG-TERM EFFICACY AND NOVEL MECHANISM OF ACTION AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE
Jul 30, 2008
|
12.9 KB
|
| |
SAN FRANCISCO (July 30, 2008) – Medivation, Inc. (NASDAQ: MDVN) today announced new data showing that its investigational drug Dimebon continues to produce broad, clinically meaningful benefits in Alzheimer's disease patients after long-term dosing, and appears to operate
through a novel mechanism of action. These data were presented today ...
|
|
|
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Jul 17, 2008
|
13.2 KB
|
| |
SAN FRANCISCO, July 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with ...
|
|
|
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Jul 7, 2008
|
12.8 KB
|
| |
SAN FRANCISCO, July 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced top-line results of a Phase 2 study showing that its investigational drug Dimebon(TM) significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantl...
|
|
|
Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease
Jul 3, 2008
|
9.0 KB
|
| |
SAN FRANCISCO, July 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of dimebon(TM) in Huntington's disease.
Tele...
|
|
|
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
Jun 9, 2008
|
12.1 KB
|
| |
SAN FRANCISCO, June 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced it has initiated dosing of patients in its second pivotal Phase 3 trial of the investigational drug Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease (AD). The international, double-blind, placebo-controlled ...
|
|
|
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Jun 2, 2008
|
12.0 KB
|
| |
SAN FRANCISCO and CHICAGO, June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific a...
|
|
|
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
May 15, 2008
|
10.4 KB
|
| |
SAN FRANCISCO, May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chic...
|
|
|
Medivation Announces Participation in Upcoming Conferences
May 13, 2008
|
8.1 KB
|
| |
SAN FRANCISCO, May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences.
-- Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday,
May 20 at 2:40 p.m. local tim...
|
|
|
Medivation Reports First Quarter 2008 Financial Results and Provides Corporate Update
May 1, 2008
|
16.2 KB
|
| |
SAN FRANCISCO, May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended March 31, 2008.
"We are dedicated to developing product candidates as rapidly, efficiently and cost-effectively as possible, as patients are in desperat...
|
|
|
Medivation Announces Participation in Upcoming Conferences
Apr 30, 2008
|
8.1 KB
|
| |
SAN FRANCISCO, April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences.
-- Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5 at
2:00 p.m. Eastern Time at T...
|
|
|
Medivation Announces First Quarter 2008 Teleconference and Webcast on May 1, 2008
Apr 24, 2008
|
7.8 KB
|
| |
SAN FRANCISCO, April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will webcast a teleconference with management to discuss first quarter 2008 progress and provide a general business update on Thursday, May 1, 2008, at 4:30 p.m. Eastern time. A financial results press release for ...
|
|
| |
AAN abstract for April 17
Apr 17, 2008
|
17.7 KB
|
|
Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
Apr 17, 2008
|
12.0 KB
|
| |
SAN FRANCISCO and CHICAGO, April 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that Alzheimer's patients treated with the investigational drug Dimebon(TM) showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in ...
|
|
| |
AAN abstract for April 15
Apr 15, 2008
|
15.9 KB
|
|
The press releases may contain historical information and may no longer be accurate. Medivation disclaims any responsibility to update such information.
|
 Briefcase
 Download Library
 Email Alerts
 RSS News Feeds
Amanda Mason
WeissComm Partners
1251 6th Ave.
Suite 3500
New York, NY 10020
Phone: 212-301-7221
Fax: 212-867-3249
For a high resolution copy of our logo (eps file), click here.
|
